$GNPX: Congressman Buying, Tiny 2.2M Float, Massive Diabetes News, Squeeze Imminent?

GNPX (Genprex, Inc.) is showing a setup that we rarely see in micro-caps: actual Congressional "insider" buying combined with a float so small that any volume sends it into orbit.

1. The "Follow the Money" Play 🏛️

Congressman Tim Moore (R-NC) has been loading up on GNPX. He disclosed multiple purchases between October and December 2025, ranging from $15k to $50k.

• Why this matters: Most Reps trade S&P 500 giants. It is highly unusual for a Congressman to buy a micro-cap biotech with a $4M market cap unless they see something massive on the horizon.

• Timing: His buys happened just before this week’s breakthrough news.

2. The Clinical Catalyst :

Yesterday (Jan 7, 2026), Genprex dropped a bomb: Their GPX-002 gene therapy successfully rejuvenated exhausted beta cells and normalized glucose levels in primate models for Type 2 Diabetes. 

• They have already requested an FDA meeting for Q1 2026 to move toward human trials. 
• This isn't just a "concept"—they've already moved manufacturing to a CDMO for scale-up. 

3. The "Low Float" Math 📈

This is the part that creates the squeeze:
• Public Float: Only ~2.2 Million shares. 
• Daily Volume: We’ve seen 1M+ shares trade in a day recently. That means nearly 50% of the float is turning over daily.

• Short Interest: Currently around 8.3% of the float. In a normal stock, that’s low. In a 2.2M float stock, that is a massive "coiled spring" because there are no shares left to borrow.

The Bottom Line:

The stock has been beaten down from $50+ to the $1.90 range, but the combination of a Congressional "stamp of approval," a massive diabetes breakthrough, and a micro-float means this could move 50–100% on a single green day.

Upcoming Catalyst: FDA meeting response in Q1.

Disclaimer: Not financial advice. Micro-cap biotechs are extremely volatile. Do your own DD.